PURPOSE: Adequate monitoring of the effect of the direct thrombin inhibitor argatroban may facilitate individualized dosing and perioperative management of anticoagulation. Ecarin Clotting Time is proposed for this purpose, but has the major disadvantage of limited availability. There is a point-of-care applicable ecarin-activated test modification for rotational thrombelastometry (ROTEM®) which is sensitive to direct thrombin inhibitors. The aim of the study was to evaluate the correlation between argatroban concentration and this ecarin modified thrombelastometry (EMT). METHODS: In this in vitro experiment, blood drawn from healthy volunteers was spiked with argatroban at clinically relevant concentrations and analyzed with ROTEM® using EMT. The main endpoint was the clotting time (CT). RESULTS: EMT-CT was prolonged with increasing argatroban concentrations (from 83.3 ± 6.7 s without argatroban to 743.5 ± 138.2 s at 2 μg/ml argatroban). The correlation between argatroban concentration and EMT-CT was high (r = 0.94) and statistically significant (p < 0.01). CONCLUSION: These promising preclinical results mandate further clinical research to determine an EMT-CT target range regarding the clinical outcomes of thrombosis and bleeding.
PURPOSE: Adequate monitoring of the effect of the direct thrombin inhibitor argatroban may facilitate individualized dosing and perioperative management of anticoagulation. Ecarin Clotting Time is proposed for this purpose, but has the major disadvantage of limited availability. There is a point-of-care applicable ecarin-activated test modification for rotational thrombelastometry (ROTEM®) which is sensitive to direct thrombin inhibitors. The aim of the study was to evaluate the correlation between argatroban concentration and this ecarin modified thrombelastometry (EMT). METHODS: In this in vitro experiment, blood drawn from healthy volunteers was spiked with argatroban at clinically relevant concentrations and analyzed with ROTEM® using EMT. The main endpoint was the clotting time (CT). RESULTS: EMT-CT was prolonged with increasing argatroban concentrations (from 83.3 ± 6.7 s without argatroban to 743.5 ± 138.2 s at 2 μg/ml argatroban). The correlation between argatroban concentration and EMT-CT was high (r = 0.94) and statistically significant (p < 0.01). CONCLUSION: These promising preclinical results mandate further clinical research to determine an EMT-CT target range regarding the clinical outcomes of thrombosis and bleeding.
Authors: J M Walenga; A R Fasanella; O Iqbal; D A Hoppensteadt; S Ahmad; D E Wallis; M Bakhos Journal: Semin Thromb Hemost Date: 1999 Impact factor: 4.180
Authors: M Mittermayr; J Margreiter; C Velik-Salchner; A Klingler; W Streif; D Fries; P Innerhofer Journal: Br J Anaesth Date: 2005-07-15 Impact factor: 9.166
Authors: Eva Schaden; Andreas Schober; Stefan Hacker; Christian Spiss; Astrid Chiari; Sibylle Kozek-Langenecker Journal: Blood Coagul Fibrinolysis Date: 2010-04 Impact factor: 1.276
Authors: Robert Siegmund; Klas Boer; Katrin Poeschel; Gunter Wolf; Thomas Deufel; Michael Kiehntopf Journal: Thromb Res Date: 2008-04-22 Impact factor: 3.944
Authors: Mark Walsh; Stephanie Fritz; Daniel Hake; Michael Son; Sarah Greve; Manar Jbara; Swetha Chitta; Braxton Fritz; Adam Miller; Mary K Bader; Jonathon McCollester; Sophia Binz; Alyson Liew-Spilger; Scott Thomas; Anton Crepinsek; Faisal Shariff; Victoria Ploplis; Francis J Castellino Journal: Curr Drug Targets Date: 2016 Impact factor: 3.465
Authors: Martin Beiderlinden; Patrick Werner; Astrid Bahlmann; Johann Kemper; Tobias Brezina; Maximilian Schäfer; Klaus Görlinger; Holger Seidel; Peter Kienbaum; Tanja A Treschan Journal: BMC Anesthesiol Date: 2018-02-09 Impact factor: 2.217